Mometasona Ciclum (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in nasal epithelial cells, altering gene transcription to suppress pro‑inflammatory cytokines and chemokines while enhancing anti‑inflammatory proteins. This reduces swelling, mucus production, and immune cell infiltration, leading to symptom improvement in the nasal passages.

The specific dosing regimen for Mometasona Ciclum is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions and the product label for the correct number of sprays and frequency.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Mometasone furoate is a high‑potency intranasal corticosteroid with a low systemic bioavailability, offering strong anti‑inflammatory effects while minimizing systemic exposure. Compared with older agents such as fluticasone or budesonide, it often provides comparable or superior symptom control with once‑daily dosing for many patients.

Store the nasal spray at temperatures below 25 °C (77 °F), in its original packaging, and protect it from moisture and direct sunlight. Do not freeze the product. Keep the device out of reach of children and check the expiry date before use.

Mometasona Ciclum is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator while breathing in gently through the nose. The same procedure is repeated in the other nostril if required.

Serious but rare risks include nasal septal perforation, suppression of the hypothalamic‑pituitary‑adrenal axis, cataract or glaucoma development, severe allergic reactions (anaphylaxis), and opportunistic fungal infections of the nasal mucosa. Any unusual symptoms should be reported to a healthcare professional promptly.

Patients with known hypersensitivity to mometasone furoate or any component of the formulation should avoid use. Individuals with active untreated infections of the nasal passages, recent nasal surgery, or severe ocular herpes should also consult a physician before using this nasal corticosteroid.